News | December 26, 2023
BioVaxys executes LoI for major Immunotherapeutics technology acquisition
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Subscribe To Our Newsletter & Stay Updated
